Table 5.
Variable | HR | 95% CI | p |
---|---|---|---|
Clinical stage | |||
II | 1 | 0.003 | |
III | 5.903 | 1.861–18.728 | |
Podoplanin | |||
Negative | 1 | 0.050 | |
Positive | 2.839 | 1.011–8.128 | |
Age | 1.010 | 0.978–1.044 | 0.543 |
Treatment | |||
Surgery | 1 | 0.978 | |
Radiotherapy | 0.981 | 0.254–3.785 |
Variable | HR | 95% CI | p |
---|---|---|---|
Clinical stage | |||
II | 1 | 0.003 | |
III | 5.903 | 1.861–18.728 | |
Podoplanin | |||
Negative | 1 | 0.050 | |
Positive | 2.839 | 1.011–8.128 | |
Age | 1.010 | 0.978–1.044 | 0.543 |
Treatment | |||
Surgery | 1 | 0.978 | |
Radiotherapy | 0.981 | 0.254–3.785 |